©2025 Stanford Medicine
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Recruiting
Trial ID: NCT07015190
Purpose
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Official Title
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)
Stanford Investigator(s)
Pauline Funchain
Associate Professor of Medicine (Oncology)
Eligibility
Inclusion Criteria:
* Primary non-metastatic uveal melanoma
* Able and willing to provide written, informed consent before initiation of any study-related procedures, and in the opinion of the Investigator, to comply with all study requirements
* ECOG 0 or 1
* Adequate organ function
Exclusion Criteria:
* Previous treatment for UM
* Evidence of metastatic UM
* Attributes that necessitate enucleation regardless of response to therapy
* Evidence of progressive secondary underlying ocular disease that would confound longitudinal VA assessments
* Presence of a malignant disease other than the one being treated in this study
Intervention(s):
drug: Darovasertib
procedure: Primary Local Therapy
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305